US$ 26.34
noom glp-1 rx jumps into off-brand weight loss drug market The Noom Engagement Report: New
Description
Excluding GLP-1, pharma IRR drops from 5.9% to 3.8%
Companies are investing in research and development

Does the use of glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP) agonists have clinically significant effects on residual gastric volume (RGV) in the periprocedural period
Hydration matters when you're on weight loss medications like GLP-1s
